On Jun. 30, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine candidate against COVID-19.

The agreement included up to 414 million doses available to participants of the COVAX Facility.